MD Anderson's fifth annual Boot Walk to End Cancer® goes virtual Nov. 7
HOUSTON ― The University of Texas MD Anderson Cancer Center will host the fifth annual Boot Walk to End Cancer® virtually on Saturday, Nov. 7. The virtual walk will take place online and in neighborhoods across the country in an effort to keep participants, their families and their communities safe and as part of MD Anderson's commitment to prioritizing the health and safety of patients, workforce members and the greater Houston community...
MD Anderson, UT Austin Announce First Collaborative Projects in United Fight to End Cancer
Cancer remains one of the leading causes of death worldwide. While advances in cancer diagnoses and treatments are promising, more is needed...
MD Anderson and Allogene Therapeutics announce strategic collaboration to accelerate advancement of allogeneic CAR T therapy (AlloCAR T)
The University of Texas MD Anderson Cancer Center and Allogene Therapeutics, Inc. today announced a strategic five-year collaboration agreement...
Dual checkpoint blockade promising as pre-surgical approach for certain patients with localized bladder cancer
Neoadjuvant, or pre-surgical, combination treatment with the immune checkpoint inhibitors tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-1) was well-tolerated and showed early signs of activity in certain patients with localized bladder cancer who do not have standard treatment options available, according to a Phase I clinical trial conducted by The University of Texas MD Anderson Cancer Center.
This represents the first...
Study finds cancer mutations accumulate in distinct regions based on structure of genome and mutational causes
A new study from researchers at The University of Texas MD Anderson Cancer Center has discovered that mutations found in cancers do not accumulate...
Next-gen bioinformatics tool enables big data analysis without programming expertise
A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly,...
MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
Monica Johnson receives Julie and Ben Rogers Award for Excellence
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor...
MD Anderson and Xencor enter strategic collaboration to advance investigational XmAb® drug candidates
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...